Rain Enhancement Technologies Holdco, Inc. (RAIN) Q1 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the RAINN Oncology, Inc. First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star then zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry. Thank you. Dan, you might begin. Thank you, operator, and good afternoon, everyone. With me today on the phone are Avinash Vellanki, Chief Executive Officer of RAIN Oncology, Dr. Robert Doble, Chief Scientific Officer, Dr. Richard Bryce, Chief Medical Officer, and Nelson Caviton, SVP of Finance. During today's call, Avinash will provide an update on the broader strategic vision for the Milidemetan franchise. Bob will review the biology and rationale of P53 reactivation and discuss possibilities for future clinical development of Milidemetan based on non-clinical research. Richard will provide an update on RAIN's clinical strategy, and Nelson will review the financials. Before we begin, I would like to remind you that statements made during this conference call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon RAIN's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements, as a result of various risks and uncertainties as described in RAIN's most recent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission and other SEC filings. All ...